Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?
The investment case for Zoetis Inc. (NYSE:ZTS) has changed significantly since declining demand in its U.S. companion-animal ...
Model output · Signal date 2026-10-16
Zoetis Inc. (ZTS) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Bottom 35%
of 5171 stocks scored
Rank correlation · 90D
35.0%
Spearman, 357 dates
Market Cap
$32.40B
large-cap · #18 of 60 peers
Summary
Zoetis Inc. (ZTS) stock forecast summary
Our AI ranks Zoetis Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Zoetis Inc. is a large-cap company with a market capitalization of $32.40B. It ranks number 18 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ZTS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.3%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ZTS included.
Follow ZTS freePrice
ZTS price chart and AI forecast
Cross-section · 2026-10-16
How ZTS ranks among 5171 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Zoetis Inc. (ZTS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | ZTS | Rank |
|---|---|---|
| Market Cap | $32.40B | 18/60 |
| P/E Ratio | 12.92x | 26/32 |
| P/B Ratio | 10.29x | 15/42 |
| Dividend Yield | 2.74% | 3/10 |
| EPS | $6.07 | – |
| Book Value/Share | $7.62 | – |
| Revenue/Share | $23.03 | – |
| FCF/Share | $5.73 | – |
Profitability & Margins
| Metric | ZTS | Rank |
|---|---|---|
| ROE | 83.1% | 2/38 |
| ROA | 17.4% | 7/43 |
| Gross Margin | 71.5% | 24/35 |
| Net Margin | 27.5% | 8/35 |
| EBT Margin | 34.4% | 11/46 |
| Tax Rate | 20.1% | – |
Financial Health
| Metric | ZTS | Rank |
|---|---|---|
| Current Ratio | 3.08x | 30/59 |
| Quick Ratio | 1.84x | 20/43 |
| D/E Ratio | 3.79x | 5/48 |
| Financial Leverage | 4.79x | 5/48 |
| Working Capital | $4.29B | 11/59 |
Cash Flow
| Metric | ZTS | Rank |
|---|---|---|
| Operating Cash Flow | $2.89B | 17/59 |
| Free Cash Flow | $2.37B | 14/50 |
| Capital Spending | -$521M | 36/50 |
| OCF Growth YoY | -1.4% | 22/33 |
| FCF Growth YoY | 6.6% | 12/31 |
| FCF/Sales | 24.9% | 10/42 |
| CapEx/Sales | 5.5% | 11/42 |
Operational Efficiency
| Metric | ZTS | Rank |
|---|---|---|
| Asset Turnover | 0.63x | 13/40 |
| Receivables Turnover | 6.1x | 11/37 |
| Inventory Turnover | 1.1x | 25/35 |
| Fixed Assets Turnover | 2.5x | 35/41 |
| Days Sales Outstanding | 60 days | 27/37 |
| Days Inventory | 347 days | 11/35 |
| Payables Period | 61 days | 22/25 |
| Cash Conversion Cycle | 346 days | 5/23 |
Income Statement
| Metric | ZTS | Rank |
|---|---|---|
| Total Revenue | $9.52B | 15/46 |
| Net Income | $2.62B | 13/46 |
| R&D Expense | $722M | 25/58 |
| SG&A Expense | $2.38B | 15/40 |
| Cost of Goods Sold | $2.71B | 16/36 |
Dividend & Shareholder Information
| Metric | ZTS | Rank |
|---|---|---|
| Dividends Per Share | $2.15 | – |
| Payout Ratio | 35.4% | 8/10 |
| Shares Outstanding | 413M | – |
| Net Income Growth | 0.1% | 10/18 |
| EPS Growth | 4.5% | 11/24 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $6.36B | 42.2% of assets |
| Cash & Short-term Investments | $1.48B | 9.8% of assets |
| Accounts Receivable | $1.57B | 10.4% of assets |
| Inventory | $2.57B | 17.1% of assets |
| Total Liabilities | $11.93B | 79.1% of assets |
| Short-term Debt | $1.61B | 10.7% of assets |
Quarterly Financial Reports
ZTS quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Zoetis Inc. (ZTS) industry peers
Companies classified under the same SEC industry code as Zoetis Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ZTS Zoetis Inc. | ▼ | $32.40B |
| LLY Eli Lilly & Co | ▼ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▼ | $504.46B |
| MRK Merck & Co., Inc. | ▶ | $360.08B |
| NVS Novartis Ag | ▼ | $286.95B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▼ | $167.80B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.95B |
| BMY Bristol Myers Squibb Co | ▼ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $99.33B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $82.34B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $60.76B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $47.91B |
| ONC Beone Medicines Ltd. | ▲ | $42.53B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.29B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.59B |
| GMAB Genmab A/S | ▶ | $23.80B |
| UTHR United Therapeutics Corp | ▼ | $23.23B |
| INSM Insmed Inc | ▶ | $21.02B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▶ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| SMMT Summit Therapeutics Inc. | ▲ | $12.26B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▶ | $11.77B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.77B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.39B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.89B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.84B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $6.06B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.09B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.72B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.83B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.83B |
Where ZTS sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Zoetis Inc. (ZTS) stock news
Law Offices of Frank R. Cruz Encourages Zoetis Inc. (ZTS) Shareholders To Inquire About Securities Fraud Class Action
On August 5, 2025, Zoetis released its second quarter 2025 financial results, reporting weakened demand trends within its Companion Animal portfolio. On this news, Zoetis’ stock price fell $5.69, or 3 ...
Zoetis Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Shares of Zoetis Inc. ZTS advanced 1.33% to $75.29 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.11% to 7,718.94 and ...
FAQ
Zoetis Inc. (ZTS) stock forecast FAQ
What is the Zoetis Inc. (ZTS) stock forecast?
Our AI ranks Zoetis Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Zoetis Inc. stock predictions?
For ZTS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Zoetis Inc. forecasts updated?
Zoetis Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Zoetis Inc.'s industry peers?
60 issuers in our coverage, ZTS included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.